secwatch.observer — SEC 8-K summary
======================================

Issuer:     Greenwich LifeSciences, Inc. (GLSI)
CIK:        0001799788
Form:       8-K
Filed at:   2021-12-13T23:59:59+00:00
Accession:  0001493152-21-031170
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Greenwich LifeSciences reports 5-year GP2 Phase IIb data: baseline immune response predicts recurrence
--------------------------------------------------------------------------------

- 22.8% of 145 patients had positive baseline DTH response to GP2; 24.2% recurrence rate over 5 years (median 99 days).
- Patients without baseline response had 12.5% recurrence rate with median time to recurrence of 438 days.
- HER2+ patients completing GP2 primary series showed 100% DFS vs 89.4% for placebo (p=0.0338) over 5 years.
- GP2 treatment was well tolerated with no serious adverse events attributed to GLSI-100.
- Company plans Phase III trial in 2022 and exploration of GP2-specific CAR-T cell candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799788/000149315221031170/0001493152-21-031170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799788/000149315221031170/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-031170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer